Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
Science and Technology Commission of Shanghai Municipality
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
Zhiguo Hou, Chuyu Jing, Boer Shan, Huaying Wang et al.
Citations
2 citations
Journal
BMC Medicine
Topics
Endometrial and Cervical Cancer Treatments
Field-Weighted Citation Impact (FWCI)
0.58
article
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
Zhiguo Hou, Chuyu Jing, Boer Shan, Huaying Wang, Wenqing Zhu, Huijuan Yang, Jing Lü, Wei Zhang, Haiming Li, Xi Cheng, Yi Zhang, Ting Yang, Wenjuan Tian, Ren Yulan, Tingting Wang
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC MedicineVol. 22(1)
Institutions
Shanghai Medical College of Fudan University (CN), Shanghai Jiao Tong University (CN), Renji Hospital (CN), Fudan University Shanghai Cancer Center (CN), Jiangsu Hengrui Medicine (China) (CN)
Funders
National Natural Science Foundation of China, Fudan University, Science and Technology Commission of Shanghai Municipality
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial — Zhiguo Hou, Chuyu Jing, et al. · BMC Medicine (2024) | TGRS Research Map | TGRS